Doximity Aktie News

Doximity's sales growth slowed to 10% in Q3, and its net income dipped. Worse yet, the company guided for sales growth of only 4% in the upcoming quarter.

Doximity, Inc. (DOCS) Q3 2026 Earnings Call Transcript

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, announced today that Doximity Dialer has been named the #1 Telehealth Video Conferencing Platform in the 2026 Best in KLAS Report. This is the fifth consecutive year that Doximity has earned the top spot, underscoring its position as a trusted, long-term partner for physicia...

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 third quarter ended December 31, 2025. “We're proud to deliver another quarter of strong profits and record engagement,” said Jeff Tangney, co-founder and CEO of Doximity. “Our newsfeed had more than 1 million quarterly active presc...

Medicare will no longer cover telemedicine services for many patients. This change will affect Teladoc Health, which was already struggling.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Doximity Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.

At the start of the new year, investors seeking a fresh approach might consider stocks that are positioned for a reset. Companies trading at or near their lowest level for 2025 could be primed for gains in the new year if conditions are right.

Doximity's Q2 results show record engagement and accelerating adoption of AI workflow tools, signaling deeper physician reliance on the platform. Revenue quality is improving as pharma clients shift from one-off ad buys to longer-term integrated programs. Doximity has a strong Rule-of-50 profile with high margins and $890m cash but no debt.